Prestige Consumer Healthcare (NYSE:PBH) Releases FY25 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY25 earnings guidance on Thursday. The company provided EPS guidance of $4.40 to $4.46 for the period, compared to the consensus EPS estimate of $4.42. The company issued revenue guidance of $1.125 billion to $1.140 billion, compared to the consensus revenue estimate of $1.13 billion. Prestige Consumer Healthcare also updated its FY 2025 guidance to 4.460-4.460 EPS.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on PBH shares. DA Davidson upped their price objective on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Jefferies Financial Group restated a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $94.20.

Prestige Consumer Healthcare Price Performance

PBH stock traded up $1.97 during mid-day trading on Thursday, hitting $79.61. 10,788 shares of the stock were exchanged, compared to its average volume of 245,974. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. The business has a fifty day moving average price of $72.31 and a 200 day moving average price of $69.71. Prestige Consumer Healthcare has a 12 month low of $56.61 and a 12 month high of $79.82. The stock has a market capitalization of $3.95 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 2.08 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The company had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. During the same quarter in the previous year, the business earned $1.06 EPS. Prestige Consumer Healthcare’s revenue was down 4.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Prestige Consumer Healthcare will post 4.43 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.